As far as cost goes gallium is by far the cheapest.
And one could argue that being isotope and targeting modality agnostic and flexible means treatment can be tailored specifically for certain indications rather than being hamstrung by having a rigid platform.
As an example with TLX591 the lutetium 177 has a half life of 6.7 days and the monoclonal antibody it uses for targeting results in tumour retention of up to two weeks.
Cu67 has a half life of 2.5 days.
It will be interesting to see how they compare when overall survival data is available as TLX591's overall survival from the first trial is 43 months compared to 15 months for pluvicto.
That other company is using antibody fragments, antibodies proper and small molecules along with a multitude of different isotopes.
It's far too early to say which company's approach wins out but there's no reason not to hold both.
CU6 Price at posting:
$3.78 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)